Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Making Significant Advances in Drug Delivery

Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed one of the most innovative drug-delivery systems seen in years, a system that can be used to deliver a wide range of drugs in a more palatable and effective way. Seattle Genetics Inc. (NASDAQ: SGEN) is developing anti-cancer drugs whose delivery systems deliver killer treatments directly to harmful cells. Cancer-treatment company Exelixis Inc. (NASDAQ: EXEL) has recently entered into a partnership specifically to develop innovative new drugs. Axsome Therapeutics Inc. (NASDAQ: AXSM) uses a variety of delivery mechanisms to treat illnesses of the central nervous system, including narcolepsy, migraines and depression. Provention Bio Inc. (NASDAQ: PRVB) is focused on immune diseases and has recently seen significant progress in the development of lupus and diabetes drugs.